Disseminated Histoplasmosis Presenting as Crescentic Glomerulonephritis and Secondary Hemophagocytic Lymphohistiocytosis in a Renal Transplant Recipient: A Case Report
Case Reports in Nephrology and Dialysis · 13.11.2026
DOI: 10.1159/cnd/abxag012 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Nephrology and Dialysis, online erschienen am 13.11.2026. Verfasst von Atta Ullah und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Disseminated histoplasmosis is an important opportunistic infection in solid organ transplant recipients and may present with nonspecific systemic manifestations that delay diagnosis. Secondary hemophagocytic lymphohistiocytosis and crescentic glomerulonephritis are rare but potentially life-threatening complications. We report an unusual case of disseminated histoplasmosis in a kidney transplant recipient complicated by both secondary hemophagocytic lymphohistiocytosis and crescentic glomerulonephritis involving the renal allograft. Case presentation: A 48-year-old African American man with end-stage renal disease secondary to hypertension underwent deceased donor kidney transplantation and was maintained on belatacept, mycophenolate, and prednisone. Eight months after transplantation, he presented with malaise, night sweats, anorexia, gastrointestinal symptoms, acute kidney injury, hyponatremia, pancytopenia, transaminitis, elevated inflammatory markers, and splenomegaly. Histoplasma antigen testing was positive, and bronchoalveolar lavage with lymph node biopsy confirmed Histoplasma capsulatum. Bone marrow biopsy demonstrated scattered hemophagocytic histiocytes, with fungal organisms visualized within histiocytes, consistent with secondary hemophagocytic lymphohistiocytosis. Renal allograft biopsy showed focal crescentic glomerulonephritis with mild T cell-mediated rejection, macrophage activation, and Histoplasma yeast forms confirmed by Grocott methenamine silver staining. The patient received liposomal amphotericin B for 14 days, followed by isavuconazonium sulfate. Although at least 1 year of antifungal therapy was intended, he self-discontinued isavuconazonium sulfate after 68 days because of headache and brain fog. Mycophenolate was withheld at presentation and remained on hold throughout and beyond antifungal administration. Hemodialysis was discontinued during the second week of amphotericin therapy, and renal function returned to the prior baseline serum creatinine of 2.4 mg/dL at clinic follow-up approximately 4 weeks after initial presentation.
Conclusions
This case highlights the need to consider disseminated histoplasmosis in renal transplant recipients presenting with systemic inflammation, cytopenias, and renal allograft dysfunction, particularly when features of hemophagocytic lymphohistiocytosis are present. Early tissue diagnosis and prompt antifungal therapy, combined with careful immunosuppression management, may be critical for preserving patient and allograft outcomes.
Zitieren
APA
Ullah, A., Sodhi, R., Jain, D., Akkina, S., Clark, N. M., Picken, M. M., & Peev, V. (2026). Disseminated Histoplasmosis Presenting as Crescentic Glomerulonephritis and Secondary Hemophagocytic Lymphohistiocytosis in a Renal Transplant Recipient: A Case Report. Case Reports in Nephrology and Dialysis. https://doi.org/10.1159/cnd/abxag012
Vancouver
Ullah A, Sodhi R, Jain D, Akkina S, Clark NM, Picken MM, et al. Disseminated Histoplasmosis Presenting as Crescentic Glomerulonephritis and Secondary Hemophagocytic Lymphohistiocytosis in a Renal Transplant Recipient: A Case Report. Case Reports in Nephrology and Dialysis. 2026. doi:10.1159/cnd/abxag012
BibTeX
@article{Ullah2026,
author = {Ullah, Atta and Sodhi, Rupinder and Jain, Divya and Akkina, Sanjeev and Clark, Nina M and Picken, Maria M and Peev, Vasil},
title = {Disseminated Histoplasmosis Presenting as Crescentic Glomerulonephritis and Secondary Hemophagocytic Lymphohistiocytosis in a Renal Transplant Recipient: A Case Report},
journal = {Case Reports in Nephrology and Dialysis},
year = {2026},
doi = {10.1159/cnd/abxag012}
}
EUVIMED